An EU approval for an HIV therapy enhancing drug, mixed late-stage reviews for another big pharmaceutical company, and a rough week for two biotech standouts are this week's top stories.
How about a 50% gain in one week? That's the worst performance among these health-care high flyers.
The details behind Roche's deal with Pacific Biosciences of California.
Is Pacific Biosciences' new arrangement with Roche a good deal? Mr. Market gives PacBio's deal a big thumbs up.
Covance is doing well with its contract research business.
Two important things you need to know about the future of Illumina.
Exact Sciences' roller coaster ride is now on a huge upswing. Time to buy -- or sell?
Let's see what the numbers say about Sequenom (SQNM).
The medical-technology company isn't well known, but investors have pushed Waters stock up toward all-time records.
With the potential for an epidemic at hand, we look at things from a glass-half-full perspective.